Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Systemic Mastocytosis Patient Experience from Mast Cell Connect, the First Patient-Reported Registry for Mastocytosis

Philina Lee, PhD, Tracy I. George, MD, Hongliang Shi, MS, Erica K. Evans, PhD, Teghpal Singh, PhD, Anthony L Boral, MD PhD, Vanessa Rangel Miller, MS, MBA, Srdan Verstovsek, MD PhD

Blood (2016) 128 (22): 4783.

https://doi.org/10.1182/blood.V128.22.4783.4783

Published: 2016

Journal Articles

Preliminary Safety and Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (SM)

Mark W. Drummond, PhD MD, Daniel J. DeAngelo, MD PhD, Michael W. Deininger, MD PhD, Deepti Radia, MBBS, MRCPI, FRCPath MSc, MD, Albert Thomas Quiery, MD, Elizabeth O Hexner, MD, Hongliang Shi, MS, Terri Alvarez-Diez, PhD, Erica K. Evans, PhD, Mary Ellen Healy, MS, Beni B. Wolf, MD PhD, Srdan Verstovsek, MD PhD

Blood (2016) 128 (22): 477.

https://doi.org/10.1182/blood.V128.22.477.477

Published: 2016

Journal Articles

Meta-Analysis of the Efficacy and Safety of Bortezomib Retreatment in Patients with Multiple Myeloma (MM)

Kevin B Knopf, MD, Mei Sheng Duh, ScD, MPH, Marie-Hélène Lafeuille, MA, Jonathan Gravel, Patrick Lefebvre, MA, Liviu Niculescu, Abbie Ba-Mancini, BS, MBA, Esprit Ma, Hongliang Shi, MS, Raymond L. Comenzo, MD

Blood (2012) 120 (21): 1863.

https://doi.org/10.1182/blood.V120.21.1863.1863

Published: 2012

Journal Articles

Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study

Shaji Kumar, MD, Ian W. Flinn, MD, PhD, Paul G Richardson, MD, Parameswaran Hari, MD, Natalie Scott Callander, MD, Stephen J. Noga, MD, PhD, A. Keith Stewart, MD, Jonathan Glass, MD, FACP, Robert M. Rifkin, MD, Jeffrey L Wolf, MD, Jose Estevam, BS, George Mulligan, PhD, Hongliang Shi, MS, Iain J. Webb, MD, FRCPC, S. Vincent Rajkumar, MD

Blood (2010) 116 (21): 621.

https://doi.org/10.1182/blood.V116.21.621.621

Published: 2010

Journal Articles

The Cost-Effectiveness of Bortezomib Plus Melphalan and Prednisone Versus Lenalidomide Plus Melphalan and Prednisone with Continuous Lenalidomide Maintenance Treatment for the Initial Treatment of Multiple Myeloma In the United States

Si-Tien Wang, MS, Hui Huang, PhD, MBA, Abbie Ba-Mancini, BS, MBA, Hongliang Shi, MS, Kristina Chen, MS, Caroline Korves, ScD, Ravinder Dhawan, PhD, Andrew Cakana, FRCPath, MD, Helgi van de Velde, Dixie-Lee W. Esseltine, MD, FRCPC, Mei S. Duh, ScD, MPH

Blood (2010) 116 (21): 2563.

https://doi.org/10.1182/blood.V116.21.2563.2563

Published: 2010

Journal Articles

Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study

Shaji Kumar, MD, Ian W Flinn, MD, PhD, Stephen J. Noga, MD, PhD, Parameswaran Hari, MD, MS, Robert M. Rifkin, MD, Natalie Scott Callander, MD, Manish Bhandari, MD, Jeffrey Lee Wolf, MD, Cristina Gasparetto, MD, Amrita Krishnan, MD, FACP, Daren D Grosman, MD, PhD, Jonathan Glass, MD, Entezam Asim Sahovic, MD, Hongliang Shi, MS, Iain J. Webb, MD, Paul Richardson, MD, S. Vincent Rajkumar, MD

Blood (2008) 112 (11): 93.

https://doi.org/10.1182/blood.V112.11.93.93

Published: 2008

NARROW

Systemic Mastocytosis Patient Experience from Mast Cell Connect, the First Patient-Reported Registry for Mastocytosis

Preliminary Safety and Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (SM)

Meta-Analysis of the Efficacy and Safety of Bortezomib Retreatment in Patients with Multiple Myeloma (MM)

Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study

The Cost-Effectiveness of Bortezomib Plus Melphalan and Prednisone Versus Lenalidomide Plus Melphalan and Prednisone with Continuous Lenalidomide Maintenance Treatment for the Initial Treatment of Multiple Myeloma In the United States

Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study

Email alerts

ASH Publications

American Society of Hematology

Systemic Mastocytosis Patient Experience from Mast Cell Connect, the First Patient-Reported Registry for Mastocytosis

Preliminary Safety and Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (SM)

Meta-Analysis of the Efficacy and Safety of Bortezomib Retreatment in Patients with Multiple Myeloma (MM)

Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study

The Cost-Effectiveness of Bortezomib Plus Melphalan and Prednisone Versus Lenalidomide Plus Melphalan and Prednisone with Continuous Lenalidomide Maintenance Treatment for the Initial Treatment of Multiple Myeloma In the United States

Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only